The Duke technology is based on a collection of serum proteins associated with the biology of lung cancer.
Myla Lai-Goldman, executive vice president and medical director of LabCorp, said: “New diagnostic tools are required for lung cancer and this technology has the potential to stratify patients that may need more aggressive follow-up treatment and monitoring.”